# Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

> **NCT07189793** · PHASE2 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 106 (estimated)

## Conditions studied

- Urinary Bladder Neoplasms
- Carcinoma, Transitional Cell
- Carcinoma in Situ of Bladder
- Non-Muscle-Invasive Bladder Cancer

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Gemcitabine (GEM)
- **DRUG:** Mitomycin C (MMC)

## Key facts

- **NCT ID:** NCT07189793
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2027-10
- **Final completion:** 2028-10
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07189793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07189793, "Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07189793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*